Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04790513 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
A Phase 3 study, sponsored by LIB Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 204
- Enrollment target
NCT04790513 is a Phase 3 study that has completed, run by LIB Therapeutics. The registered enrollment target is 204 participants.
The verdict
NCT04790513, a Phase 3 study, has completed, sponsored by LIB Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 204 participants
- Enrollment target
Study Summary
Comparison of LDL-C reductions at Week 12 of monthly (Q4W\[≤ 31 days\]) dosing of LIB003 300 mg administered subcutaneously (SC) to Q4W dosing of evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg in patients with CVD or at high risk for CVD on a stable diet and high intensity statin and other LDL-C-lowering drug therapy.
Interventions
- BIOLOGICAL alirocumab
- BIOLOGICAL lerodalcibep
- BIOLOGICAL evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04790513
The ClinicalTrials.gov registry entry for NCT04790513 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LIB Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which alirocumab is the first listed.
NCT04790513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04790513 about?
NCT04790513 is a clinical study titled "Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients". Comparison of LDL-C reductions at Week 12 of monthly (Q4W\[≤ 31 days\]) dosing of LIB003 300 mg administered subcutaneously (SC) to Q4W dosing of evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg in patients with CVD or at high risk for CVD on a stable diet and high intensity statin and o...
What is the current status of trial NCT04790513?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 204 participants. The study started on 2021-04-22. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04790513?
The interventions under investigation include: alirocumab (BIOLOGICAL), lerodalcibep (BIOLOGICAL), evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04790513?
This trial is sponsored by LIB Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.